Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARADES: Safety and PK of ODM-201 in mCRPC
NCT01317641Phase 2Completed
- Sponsor
- Orion Corporation
- Start
- Mar 2011
- Primary completion
- Jul 2013
- Modality
- Orthosteric Ligands
- Countries
- 6
01
Overview
A Phase 2 trial of darolutamide in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Orion Corporation. Started Mar 2011; status: completed.
02
Drugs
darolutamide
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT01317641.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01317641.